Zydus Cadila has received approval from the United States Food and Drug Administration (FDA) to market its generic Doxycycline capsules used for the treatment of bacterial infections in the US, the company said in a filing to the Bombay Stock Exchange (BSE) on Feb. 19.
"Zydus Cadila has received approval from the USFDA to market Doxycycline capsules USP, 50 mg, 75 mg, and 100 mg," it said.
With this approval, the company will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad.
Zydus Cadila now has 102 approvals and it has so far filed for over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-2004, it added.
On Feb. 19, Cadila shares closed at the BSE Rs 327.20, up Rs 5, or 1.55 percent.
